Silexion Therapeutics executes 1-for-10 reverse stock split effective May 28, 2026

Silexion Therapeutics completed a 1-for-10 reverse share split to maintain compliance with Nasdaq Capital Market minimum bid price listing requirements. The consolidation reduces outstanding shares from approximately 4.07 million to 407,471 issued shares while proportionally increasing par value.